Search research articles
Contact Us
Filters
Showing results (61-70 of 80) with videos related to
Page
of 8
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study
Lingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2022
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
S Scalera, B Ricciuti, M Mazzotta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancer
B Ricciuti, J V Alessi, A Elkrief, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer
Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Clinical Lung Cancer
|
February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
Adriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Joao V Alessi, Xinan Wang, Arielle Elkrief, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco
Eleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Biorxiv : the Preprint Server for Biology
|
September 30, 2024
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans
Aya Ludin, Georgia L Stirtz, Asaf Tal, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 80) with videos related to
Sort By:
Page
of 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study
Lingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2022
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
S Scalera, B Ricciuti, M Mazzotta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancer
B Ricciuti, J V Alessi, A Elkrief, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer
Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Clinical Lung Cancer
|
February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
Adriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Joao V Alessi, Xinan Wang, Arielle Elkrief, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco
Eleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Biorxiv : the Preprint Server for Biology
|
September 30, 2024
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans
Aya Ludin, Georgia L Stirtz, Asaf Tal, et al.
Page
of 8